MCID: PLS007
MIFTS: 53

Plasmodium Falciparum Malaria

Categories: Cancer diseases, Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Plasmodium Falciparum Malaria

MalaCards integrated aliases for Plasmodium Falciparum Malaria:

Name: Plasmodium Falciparum Malaria 11 14 16 31
Malaria, Falciparum 43 71
Falciparum Malaria 11 14
Malaria Fever, Subtertian 11
Malignant Tertian Fever 11
Cerebral Malaria Nos 33
Malaria Falciparum 53
Cerebral Malaria 33

Classifications:



External Ids:

Disease Ontology 11 DOID:14067
ICD9CM 34 084.0
MeSH 43 D016778
NCIt 49 C34798
SNOMED-CT 68 62676009
ICD10 31 B50 B50.0 B50.9
ICD11 33 1143114898
UMLS 71 C0024535

Summaries for Plasmodium Falciparum Malaria

Disease Ontology: 11 A malaria described as a severe form of the disease caused by a parasite Plasmodium falciparum, which is marked by irrregular recurrence of paroxysms and prolonged or continuous fever.

MalaCards based summary: Plasmodium Falciparum Malaria, also known as malaria, falciparum, is related to acute kidney failure and plasmodium vivax malaria. An important gene associated with Plasmodium Falciparum Malaria is HP (Haptoglobin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Primaquine and Piperaquine have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Plasmodium Falciparum Malaria

Diseases related to Plasmodium Falciparum Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 728)
# Related Disease Score Top Affiliating Genes
1 acute kidney failure 31.4 MB IL18 HP
2 plasmodium vivax malaria 31.4 TNF IL10 G6PD DHPS DHFR
3 disseminated intravascular coagulation 31.3 TNF MB IL10
4 parasitic helminthiasis infectious disease 31.2 TNF IL10 IFNG
5 schistosomiasis 31.1 TNF IL10 IFNG
6 bacterial sepsis 31.1 TNF IL18 IL10
7 pulmonary edema 31.0 TNF NOS2 IL10 ICAM1 HP
8 tetanus 31.0 TNF MB IL10 IFNG
9 exanthem 31.0 TNF IL18 IL10 IFNG
10 acute kidney tubular necrosis 30.9 TNF MB IL18
11 blackwater fever 30.9 MB HP G6PD
12 hepatitis a 30.9 TNF IL10 IFNG G6PD
13 thrombocytopenia 30.9 TNF SELE IL10 IFNG ICAM1 HP
14 anemia, autoimmune hemolytic 30.9 IL10 HP G6PD CD55
15 aspergillosis 30.8 TNF IL18 IL10 IFNG
16 bilirubin metabolic disorder 30.8 TNF MB IL10 HP G6PD
17 dengue disease 30.8 TNF IL10 CCL4
18 hepatitis e 30.8 TNF IL10 IFNG
19 guillain-barre syndrome 30.8 TNF ICAM1 HP
20 glucosephosphate dehydrogenase deficiency 30.8 TNF HP HBB G6PD
21 bacterial meningitis 30.8 TNF IL10 CCL4
22 hemophagocytic lymphohistiocytosis 30.7 TNF IL18 IL10 IFNG
23 gastroenteritis 30.7 TNF IL10 IFNG
24 sickle cell anemia 30.7 TNF SELE ICAM1 HP HBB G6PD
25 stomatitis 30.6 TNF IL10 IFNG
26 chickenpox 30.6 TNF IL10 IFNG
27 q fever 30.6 TNF IL10 IFNG
28 adult respiratory distress syndrome 30.6 TNF SELE NOS2 MIF IL10 FCGR2A
29 common cold 30.6 TNF IL10 ICAM1
30 acquired immunodeficiency syndrome 30.5 TNF SELE NOS2 IL10 IFNG ICAM1
31 immune deficiency disease 30.5 TNF IL18 IL10 IFNG FCGR2A DHFR
32 babesiosis 30.5 TNF IL10 HP CD36
33 dermatitis 30.5 TNF IL18 IL10 IFNG
34 purpura 30.5 TNF IL10 IFNG FCGR2A
35 rhinitis 30.5 TNF IL10 IFNG ICAM1
36 herpes zoster 30.5 IL10 IFNG FCGR2A DHFR
37 melioidosis 30.5 TNF IL18 IL10 IFNG
38 salmonellosis 30.5 TNF IL18 IL10 IFNG
39 brucellosis 30.5 TNF IL18 IL10 IFNG
40 encephalitis 30.5 TNF NOS2 IL10 CCL4
41 hemoglobinuria 30.5 MB HP G6PD CR1 CD55
42 pancytopenia 30.5 IFNG HP DHFR CD55
43 allergic asthma 30.5 IL18 IL10 IFNG ICAM1
44 hemolytic anemia 30.5 HP HBB G6PD CR1 CD55
45 alpha-thalassemia 30.4 TNF HP HBB G6PD
46 bronchopneumonia 30.4 TNF IL10 HP
47 vasculitis 30.4 TNF SELE IL10 ICAM1
48 cryptococcal meningitis 30.4 TNF IL10 IFNG
49 mucormycosis 30.4 TNF IL10 IFNG
50 neuritis 30.4 TNF IL10 IFNG CCL4

Graphical network of the top 20 diseases related to Plasmodium Falciparum Malaria:



Diseases related to Plasmodium Falciparum Malaria

Symptoms & Phenotypes for Plasmodium Falciparum Malaria

GenomeRNAi Phenotypes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CCL4 CD36 CD55 CHIT1 CR1 DHFR
2 no effect GR00402-S-2 10.18 CCL4 CD36 CD55 CR1 DHFR DHPS

MGI Mouse Phenotypes related to Plasmodium Falciparum Malaria:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 CD36 CD55 CR1 DHFR DHPS FCGR2A
2 growth/size/body region MP:0005378 10.36 CD36 CD55 CR1 DHFR DHPS FCGR2A
3 nervous system MP:0003631 10.31 CD36 CR1 DHFR FCGR2A G6PD ICAM1
4 cellular MP:0005384 10.31 CD36 DHFR DHPS FCGR2A G6PD HBB
5 immune system MP:0005387 10.28 CD36 CD55 CHIT1 CR1 DHFR DHPS
6 muscle MP:0005369 10.25 CD36 CD55 DHFR HBB ICAM1 IFNG
7 cardiovascular system MP:0005385 10.24 CD36 CR1 DHFR FCGR2A G6PD HP
8 liver/biliary system MP:0005370 10.19 CD36 DHFR FCGR2A HBB HP IFNG
9 renal/urinary system MP:0005367 10.13 CD36 CD55 CR1 DHPS FCGR2A HP
10 hematopoietic system MP:0005397 10.11 CD36 CD55 CR1 DHFR DHPS FCGR2A
11 neoplasm MP:0002006 10.09 HP ICAM1 IFNG IL10 MIF NOS2
12 digestive/alimentary MP:0005381 10.03 CD36 FCGR2A ICAM1 IFNG IL10 IL18
13 mortality/aging MP:0010768 9.89 CD36 CD55 CR1 DHFR DHPS FCGR2A
14 respiratory system MP:0005388 9.86 FCGR2A HBB IFNG IL10 MB NOS2
15 integument MP:0010771 9.32 CD36 DHFR HBB ICAM1 IFNG IL10

Drugs & Therapeutics for Plasmodium Falciparum Malaria

Drugs for Plasmodium Falciparum Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Primaquine Approved Phase 4 90-34-6 4908
2
Piperaquine Approved, Experimental, Investigational Phase 4 4085-31-8
3
Artenimol Approved, Experimental, Investigational Phase 4 71939-50-9 540327
4
Quinidine Approved, Investigational Phase 4 56-54-2, 130-95-0, 804-63-7 1065 441074 3034034 8549
5
Lactitol Approved, Investigational Phase 4 585-86-4 157355
6
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
7
Dapsone Approved, Investigational Phase 4 80-08-0 2955
8
Nevirapine Approved Phase 4 129618-40-2 4463
9
Artemether Approved Phase 4 71963-77-4 68911 9796294
10
Lumefantrine Approved Phase 4 82186-77-4 6437380
11
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
12
Atovaquone Approved Phase 4 95233-18-4 74989
13
Proguanil Approved Phase 4 500-92-5 4923 6178111
14
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0, 19085-09-7 4993
15
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
16
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
18
Chlorproguanil Investigational Phase 4 537-21-3 22323 9571037
19
Methaqualone Illicit, Withdrawn Phase 4 72-44-6 6292
20
Pyronaridine Investigational Phase 4 74847-35-1 5485198
21 Analgesics, Non-Narcotic Phase 4
22 Analgesics Phase 4
23 Anti-Retroviral Agents Phase 4
24 Chrysarobin Phase 4
25 Atovaquone, proguanil drug combination Phase 4
26 Antimetabolites Phase 4
27 Artemisinins Phase 4
28 Artemether, Lumefantrine Drug Combination Phase 4
29 Folic Acid Antagonists Phase 4
30 Folate Phase 4
31 Vitamin B9 Phase 4
32 Vitamin B Complex Phase 4
33 Fanasil, pyrimethamine drug combination Phase 4
34
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
35
Clindamycin Approved, Vet_approved Phase 3 18323-44-9, 24729-96-2 29029
36
Acetaminophen Approved Phase 3 103-90-2 1983
37
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 9812710 6427057
38
Chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
39
Azithromycin Approved Phase 3 83905-01-5 447043
40
Fosmidomycin Experimental, Investigational Phase 3 66508-53-0 572
41 diuretics Phase 3
42
Epoetin Alfa Phase 2, Phase 3
43 Hematinics Phase 2, Phase 3
44
Clindamycin phosphate Phase 3 32603
45 Clindamycin palmitate Phase 3
46 Sulfalene Phase 3
47 Antipyretics Phase 3
48 Chloroquine diphosphate Phase 3 50-63-5
49 Antirheumatic Agents Phase 3
50 Amebicides Phase 3

Interventional clinical trials:

(show top 50) (show all 384)
# Name Status NCT ID Phase Drugs
1 Single Low-dose Primaquine Efficacy and Safety for Treatment of Uncomplicated Plasmodium Falciparum Malaria Based on Cytochrome P450 2D6 Activity in Bagamoyo District, Tanzania. Unknown status NCT03352843 Phase 4 Primaquine
2 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
3 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children Unknown status NCT01944189 Phase 4
4 Impact of Insecticide Resistance in Anopheles Arabiensis on the Effectiveness of Malaria Vector Control in Sudan Unknown status NCT01713517 Phase 4
5 Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
6 Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
7 Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
8 A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
9 Efficacy and Safety of Artesunate + Amodiaquine Combined With a Single Low Dose of Primaquine (0.25 mg/kg) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Zanzibar Completed NCT03773536 Phase 4 Artesunate-amodiaquine given with single low dose primaquine
10 A Multicentre Randomised Comparative Clinical Trial of the Efficacy of Artesunate + Amodiaquine Versus Artemether-lumefantrine (Coartem®) for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Zanzibar Completed NCT03768908 Phase 4 Artemether-lumefantrine;Artesunate + Amodiaquine
11 Randomized Study of the Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate Plus Amodiaquine Coadministered for the Treatment of Uncomplicated Falciparum Malaria in Zanzibar Completed NCT03764527 Phase 4 Artemether-lumefantrine;Coadministered Artesunate plus Amodiaquine
12 Assessing the Effectiveness of Targeted Active Case Detection Among High Risk Populations in Southern Lao PDR Completed NCT03783299 Phase 4 Artemether-lumefantrine;Primaquine Phosphate
13 Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania. Completed NCT02089841 Phase 4 Artemether-lumefantrine
14 Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi Completed NCT00125489 Phase 4 chloroquine sulfate;sulfadoxine/pyrimethamine
15 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
16 Extended Duration Artemether-lumefantrine Treatment for Malaria in Children Completed NCT03453840 Phase 4 Artemether-lumefantrine
17 Monitoring the Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine During the Treatment of Uncomplicated Plasmodium Falciparum Malaria Among Children in Yaounde, Cameroon Completed NCT04565184 Phase 4 Artesunate-amodiaquine combination;Artemether, Lumefantrine Drug Combination
18 Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack Completed NCT00445796 Phase 4 Artesunate;Amodiaquine
19 A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During the 2 Years of Follow-up, in Children in Uganda. Completed NCT00699920 Phase 4 Coarsucam;Coartem
20 Efficacy and Safety of Artesunate-amodiaquine and Artemether-lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of the Congo: a Randomized Controlled Trial Completed NCT04618523 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
21 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014 Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
22 An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older Completed NCT00444106 Phase 4 Artesunate-mefloquine;Atovaquone-proguanil;Artemether-lumefantrine
23 A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal Completed NCT00540410 Phase 4 Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination);Coartem® (arthemether+ lumefantrine)
24 A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya Completed NCT00529867 Phase 4 Artemether/lumefantrine tablets;Artemether/Lumefantrine suspension
25 Efficacy of Amodiaquine-artesunate in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children at an IPTi Site in Rural Western Kenya Completed NCT00425763 Phase 4 AQAS
26 A Nested Open Labeled Study to Compare the Effectiveness and Safety of a Fixed-dose Combination of Artesunate Plus Amodiaquine (ASAQ Winthrop®) in the Unsupervised Treatment of Uncomplicated Plasmodium Falciparum Malaria Attacks in Two Patient Groups Enrolled at Two Year-intervals in a Pilot District of Côte d'Ivoire Completed NCT01023399 Phase 4 Artesunate + Amodiaquine
27 A Phase IV Study on the Safety and Effectiveness of a Fixed-dose Combination of Artesunate and Mefloquine (Artequin[TM] Paediatric) Administered for 3 Days in Children With Uncomplicated Plasmodium Falciparum Malaria in Africa Completed NCT00978172 Phase 4 artesunate and mefloquine
28 Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria Completed NCT00167739 Phase 4 Quinine plus sulfadoxine-pyrimethamine
29 Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes Completed NCT02325180 Phase 4 Dihydroartemisinin-Piperaquine;Artemether-lumefantrine
30 Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial Completed NCT02940756 Phase 4 artesunate-amodiaquine;artemether-lumefantrine;Dihydroartemisinine-piperaquine
31 Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13 Completed NCT01755559 Phase 4 Artesunate-amodiaquine;Dihydroartemisinin-piperaquine;Artemether-lumefantrine
32 Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania Completed NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
33 Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau. Completed NCT00426439 Phase 4 Chloroquine;Artemether-lumefantrine (Coartem)
34 Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon Completed NCT02084602 Phase 4 Artesunate;Mefloquine
35 The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children With Recrudescent Malaria in Guinea-Bissau Completed NCT00137553 Phase 4 Sulfadoxine-pyrimethamine (Fansidar)
36 "Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools" Completed NCT03241901 Phase 4 Artemether-Lumefantrine Tab 20-120mg;Primaquine Phosphate 0.25 mg/kg
37 Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax® Completed NCT03201770 Phase 4 pyronaridine artesunate
38 The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians Completed NCT02434952 Phase 4 Dihydroartemisinin piperaquine (DHA PP);Primaquine
39 A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi Completed NCT00164359 Phase 4 Amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate
40 An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi Completed NCT00164710 Phase 4 sulfadoxine-pyrimethamine;amodiaquine plus sulfadoxine-pyrimethamine;amodiaquine plus artesunate;chlorproguanil-dapsone plus artesunate;lumefantrine-artemether
41 Chloroquine and Amodiaquine for Treatment of Symptomatic Children With Plasmodium Malaria in Guinea-Bissau Completed NCT00137514 Phase 4 chloroquine;amodiaquine
42 Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania Completed NCT00885287 Phase 4 Artemether-lumefantrine (AL)
43 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Completed NCT03178643 Phase 4 Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
44 Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission Completed NCT05244954 Phase 4 Dihydroartemisinin-Piperaquine;Chloroquine
45 Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan Completed NCT01019408 Phase 4 Chloroquine
46 A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects Completed NCT00859807 Phase 4 Flavoquine®, Camoquin® Suspension
47 Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial Completed NCT03916003 Phase 4 primaquine
48 Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate/Amodiaquina Combination and Artemether/Lumefantrine Combination, the Standard Treatment Recommended by the Ministry of the Social Protection in Colombia for the Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia) Completed NCT04877626 Phase 4 Artemeter plus lumefantrina vs artesunato plus amodiquina
49 Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy Completed NCT01017770 Phase 4 Artesunate-amodiaquine;Artemether-lumefantrine
50 Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients Completed NCT00233337 Phase 4 Co-artemether

Search NIH Clinical Center for Plasmodium Falciparum Malaria

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
halofantrine
Halofantrine hydrochloride
Mefloquine
Mefloquine Hydrochloride
Primaquine
Primaquine Phosphate
Proguanil
Pyrimethamine
Quinacrine
Quinacrine Monohydrochloride
Quinine
QUININE SO4 PWDR
Quinine Sulfate
Sulfadoxine

Cochrane evidence based reviews: malaria, falciparum

Genetic Tests for Plasmodium Falciparum Malaria

Anatomical Context for Plasmodium Falciparum Malaria

Organs/tissues related to Plasmodium Falciparum Malaria:

MalaCards : T Cells, Brain, Endothelial, B Cells, Liver, Bone Marrow, Whole Blood

Publications for Plasmodium Falciparum Malaria

Articles related to Plasmodium Falciparum Malaria:

(show top 50) (show all 12212)
# Title Authors PMID Year
1
Greater endothelial activation, Weibel-Palade body release and host inflammatory response to Plasmodium vivax, compared with Plasmodium falciparum: a prospective study in Papua, Indonesia. 53 62
20497057 2010
2
High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India. 53 62
20363804 2010
3
When monocytes and platelets compete: The effect of platelet count on the flow cytometric measurement of monocyte CD36. 53 62
19902557 2010
4
The first case of a class I glucose-6-phosphate dehydrogenase deficiency, G6PD Santiago de Cuba (1339 G > A), in a Chinese population as found in a survey for G6PD deficiency in northeastern and central China. 53 62
20200584 2010
5
Malaria severity and human nitric oxide synthase type 2 (NOS2) promoter haplotypes. 53 62
19859740 2010
6
Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. 53 62
20007901 2009
7
The action of falciparum malaria on the human and chimpanzee genomes compared: absence of evidence for a genomic signature of malaria at HBB and G6PD in three subspecies of chimpanzee. 53 62
19631293 2009
8
Genetic control of resistance to human malaria. 53 62
19442502 2009
9
Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. 53 62
19690618 2009
10
Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. 53 62
19380468 2009
11
CR1 levels and gene polymorphisms exhibit differential association with falciparum malaria in regions of varying disease endemicity. 53 62
19480840 2009
12
Cortisol, prolactin, cytokines and the susceptibility of pregnant Sudanese women to Plasmodium falciparum malaria. 53 62
19208295 2009
13
Quantitation of CD36 (platelet glycoprotein IV) expression on platelets and monocytes by flow cytometry: application to the study of Plasmodium falciparum malaria. 53 62
18671254 2009
14
FcgammaRIIa (CD32) polymorphism and anti-malarial IgG subclass pattern among Fulani and sympatric ethnic groups living in eastern Sudan. 53 62
19284648 2009
15
Haplotypes of IL-10 promoter variants are associated with susceptibility to severe malarial anemia and functional changes in IL-10 production. 53 62
18972133 2008
16
Variations in host genes encoding adhesion molecules and susceptibility to falciparum malaria in India. 53 62
19055786 2008
17
A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. 53 62
18954261 2008
18
dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. 53 62
19055622 2008
19
A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental Plasmodium falciparum malaria. 53 62
18179626 2008
20
Polymorphisms of TNF-enhancer and gene for FcgammaRIIa correlate with the severity of falciparum malaria in the ethnically diverse Indian population. 53 62
18194515 2008
21
High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. 53 62
19112496 2008
22
Complement activation in Ghanaian children with severe Plasmodium falciparum malaria. 53 62
18086298 2007
23
Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to Anopheles mosquitoes. 53 62
17827356 2007
24
gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria. 53 62
17557374 2007
25
Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of Plasmodium falciparum malaria in Sudanese patients. 53 62
17587350 2007
26
Detection of malaria infection via latex agglutination assay. 53 62
17511424 2007
27
Malarial pigment haemozoin, IFN-gamma, TNF-alpha, IL-1beta and LPS do not stimulate expression of inducible nitric oxide synthase and production of nitric oxide in immuno-purified human monocytes. 53 62
17543124 2007
28
[Erythrocyte polymorphism in Mali: epidemiology and resistance mechanisms against severe Plasmodium falciparum malaria]. 53 62
18225432 2007
29
Thrombocytopenia in falciparum malaria is associated with high concentrations of IL-10. 53 62
16968917 2006
30
Down-regulation of tight junction mRNAs in human endothelial cells co-cultured with Plasmodium falciparum-infected erythrocytes. 53 62
16388977 2006
31
Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with Plasmodium falciparum malaria. 53 62
16461006 2006
32
Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya. 53 62
16277654 2005
33
Carrageenans inhibit the in vitro growth of Plasmodium falciparum and cytoadhesion to CD36. 53 62
16012863 2005
34
Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. 53 62
16179085 2005
35
Plasmodium falciparum malaria in south-west Nigerian children: is the polymorphism of ICAM-1 and E-selectin genes contributing to the clinical severity of malaria? 53 62
16002039 2005
36
High levels of circulating cardiac proteins indicate cardiac impairment in African children with severe Plasmodium falciparum malaria. 53 62
16002312 2005
37
Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. 53 62
15972509 2005
38
Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria. 53 62
15973412 2005
39
A molecular epidemiologic study of point mutations for pyrimethamine-sulfadoxine resistance of Plasmodium falciparum isolates from Lao PDR. 53 62
16124424 2005
40
High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. 53 62
15653118 2005
41
Polymorphisms of the HLA-B and HLA-DRB1 genes in Thai malaria patients. 53 62
15728986 2005
42
Circulating levels of the interleukin (IL)-4 receptor and of IL-18 in patients with Plasmodium falciparum malaria. 53 62
15652447 2005
43
IFN-gamma and IL-10 mediate parasite-specific immune responses of cord blood cells induced by pregnancy-associated Plasmodium falciparum malaria. 53 62
15661939 2005
44
Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. 53 62
15900564 2005
45
Band 3/complement-mediated recognition and removal of normally senescent and pathological human erythrocytes. 53 62
16301814 2005
46
Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. 53 62
15374529 2004
47
Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. 53 62
15280204 2004
48
Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. 53 62
15385460 2004
49
Circulating concentrations of cardiac proteins in complicated and uncomplicated Plasmodium falciparum malaria. 53 62
15482402 2004
50
Prolactin induces chitotriosidase gene expression in human monocyte-derived macrophages. 53 62
15234536 2004

Variations for Plasmodium Falciparum Malaria

Expression for Plasmodium Falciparum Malaria

Search GEO for disease gene expression data for Plasmodium Falciparum Malaria.

Pathways for Plasmodium Falciparum Malaria

Pathways related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 TNF NOS2 MIF IL18 IL10 IFNG
2
Show member pathways
13.19 TNF NOS2 MIF IL18 IL10 IFNG
3
Show member pathways
12.59 SELE IFNG ICAM1 CR1 CD55
4
Show member pathways
12.56 TNF NOS2 IL18 IL10 IFNG
5
Show member pathways
12.26 TNF NOS2 MIF IFNG
6
Show member pathways
11.95 NOS2 IL18 IFNG CCL4
7
Show member pathways
11.88 TNF IL18 IL10 IFNG
8 11.87 TNF IL10 IFNG FCGR2A CD36
9 11.84 TNF IL10 IFNG CD55
10
Show member pathways
11.8 HP HBB CD36
11 11.76 TNF IL18 IL10 IFNG
12
Show member pathways
11.74 TNF IFNG FCGR2A
13 11.74 SELE IFNG ICAM1 FCGR2A
14 11.71 IL10 IFNG CD55
15 11.7 TNF IL10 IFNG
16 11.69 TNF NOS2 MIF IFNG ICAM1 FCGR2A
17 11.68 TNF IL10 IFNG CR1
18 11.6 TNF IL10 ICAM1 CCL4
19 11.58 SELE NOS2 IFNG
20
Show member pathways
11.57 TNF IL18 IL10 IFNG
21 11.53 TNF IL10 CCL4
22 11.53 IFNG IL10 IL18 TNF
23 11.49 TNF SELE IL10 ICAM1
24 11.47 TNF NOS2 IL18 IL10 ICAM1 CD36
25 11.42 TNF NOS2 IL18 IFNG
26 11.37 NOS2 IFNG ICAM1
27 11.33 TNF IL18 IL10 ICAM1 CCL4
28 11.3 TNF IL18 IFNG
29 11.25 TNF IL10 IFNG
30
Show member pathways
11.23 CCL4 IFNG IL10 TNF
31 11.21 TNF IFNG CCL4
32 11.2 TNF IL10 IFNG
33 11.13 IL18 IFNG ICAM1
34 10.92 CD36 ICAM1 TNF
35
Show member pathways
10.9 TNF SELE NOS2 MIF IFNG ICAM1
36 10.66 IFNG CR1

GO Terms for Plasmodium Falciparum Malaria

Cellular components related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.74 TNF SELE MIF IL18 IL10 IFNG
2 membrane raft GO:0045121 9.65 TNF SELE ICAM1 CD55 CD36

Biological processes related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.31 TNF NOS2 MIF IFNG CD36
2 inflammatory response GO:0006954 10.3 CCL4 IL18 MIF NOS2 SELE TNF
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.19 TNF MIF ICAM1 CD36 CCL4
4 response to lipopolysaccharide GO:0032496 10.1 TNF SELE NOS2 IL10
5 regulation of insulin secretion GO:0050796 10.08 TNF NOS2 IFNG
6 positive regulation of cell death GO:0010942 10.08 HP HBB CD36
7 positive regulation of interleukin-6 production GO:0032755 10.08 TNF NOS2 IFNG CD36
8 positive regulation of chemokine production GO:0032722 10.06 TNF IL18 IFNG
9 cellular response to amyloid-beta GO:1904646 10.05 TNF ICAM1 CD36
10 response to bacterium GO:0009617 10.02 TNF NOS2 CHIT1 CD36
11 type 2 immune response GO:0042092 9.93 IL18 IL10
12 regulation of removal of superoxide radicals GO:2000121 9.92 DHFR CD36
13 positive regulation of killing of cells of another organism GO:0051712 9.89 IFNG NOS2
14 negative regulation of cytokine production involved in immune response GO:0002719 9.86 TNF IL10
15 regulation of lipopolysaccharide-mediated signaling pathway GO:0031664 9.84 CD55 CD36
16 leukocyte migration GO:0050900 9.81 TNF SELE ICAM1
17 negative regulation of complement activation GO:0045916 9.76 CD55 CR1
18 positive regulation of cytokine production GO:0001819 9.76 IFNG IL10 MIF TNF
19 regulation of complement-dependent cytotoxicity GO:1903659 9.74 IL10 CD55
20 positive regulation of nitrogen compound metabolic process GO:0051173 9.73 IFNG TNF
21 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.71 IFNG TNF
22 positive regulation of blood microparticle formation GO:2000334 9.67 TNF CD36
23 immune response GO:0006955 9.65 TNF IL18 IL10 IFNG CHIT1 CD36
24 positive regulation of vitamin D biosynthetic process GO:0060557 9.62 TNF IFNG
25 chronic inflammatory response to antigenic stimulus GO:0002439 9.56 TNF IL10
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.23 TNF IFNG HBB CD36

Molecular functions related to Plasmodium Falciparum Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hemoglobin binding GO:0030492 9.46 HP HBB
2 NADP binding GO:0050661 9.43 NOS2 G6PD DHFR
3 cytokine activity GO:0005125 9.4 TNF MIF IL18 IL10 IFNG CCL4

Sources for Plasmodium Falciparum Malaria

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....